Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME

v3.25.2
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME      
Net sales $ 1,219,635 $ 1,159,060 $ 1,136,702
Cost of sales 429,363 389,335 366,887
Gross margin 790,272 769,725 769,815
Operating expenses:      
Selling, general and administrative 588,521 466,375 378,378
Research and development 99,496 96,664 92,493
Total operating expenses 688,017 563,039 470,871
Operating income 102,255 206,686 298,944
Other income (expense)      
Interest expense (8,509) (15,736) (11,215)
Interest income 3,886 3,323 3,410
Other non-operating income (expense), net 831 (8,584) 47,520
Total other income (expense), net (3,792) (20,997) 39,715
Earnings before income taxes 98,463 185,689 338,659
Income taxes 25,063 17,584 53,217
Net earnings 73,400 168,105 285,442
Net earnings attributable to noncontrolling interest     179
Net earnings attributable to Bio-Techne 73,400 168,105 285,263
Other comprehensive income (loss):      
Foreign currency translation income (loss) 24,002 (7,492) 4,191
Foreign currency translation reclassified to earnings with Eminence deconsolidation     119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax (5,566) (4,760) 4,793
Other comprehensive income (loss) 18,436 (12,252) 9,103
Other comprehensive income (loss) attributable to noncontrolling interest     (33)
Other comprehensive income (loss) attributable to Bio-Techne 18,436 (12,252) 9,136
Comprehensive income $ 91,836 $ 155,853 $ 294,399
Earnings per share:      
Basic (in dollars per share) $ 0.47 $ 1.07 $ 1.81
Diluted (in dollars per share) $ 0.46 $ 1.05 $ 1.76
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]      
Basic (in shares) 157,521 157,708 157,179
Diluted (in shares) 159,717 160,774 161,855